利用焦磷酸测序技术鉴定肺癌中罕见的PIK3CA突变。

Verena Schildgen, Jessica Lüsebrink, Jan D Appel, Christine Wübben, Walburga Engel-Riedel, Corinna Ludwig, Erich Stoelben, Oliver Schildgen, Michael Brockmann
{"title":"利用焦磷酸测序技术鉴定肺癌中罕见的PIK3CA突变。","authors":"Verena Schildgen,&nbsp;Jessica Lüsebrink,&nbsp;Jan D Appel,&nbsp;Christine Wübben,&nbsp;Walburga Engel-Riedel,&nbsp;Corinna Ludwig,&nbsp;Erich Stoelben,&nbsp;Oliver Schildgen,&nbsp;Michael Brockmann","doi":"10.1097/PDM.0b013e31825f5f93","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Phospatidylinositol-3-kinases (PI3K) play an important role in various cell processes. Oncogenic mutations in the PIK3CA gene, which codes for the catalytic subunit, have been identified in various malignancies and activate the PI3K/AKT/mTOR pathway, which is a critical driver of tumorigenesis.</p><p><strong>Methods: </strong>We tested 41 tumor samples with known KRAS, BRAF, and EGFR mutation status for the occurrence of mutations in the PIK3CA gene, using a pyrosequencing assay.</p><p><strong>Results: </strong>Pyrosequencing revealed 2 mutations (4.9%) in the PIK3CA gene, one in exon 9 and the other in exon 20. Both mutations have not been identified yet in lung tumor tissue.</p><p><strong>Discussion: </strong>The screening of our small patient cohort by pyrosequencing identified 2 mutations (4.9%) in PIK3CA, one in exon 9 (Q546H) and the other in exon 20 (M1043T). Both mutations have not been described in lung tumors yet and seem to be rather uncommon mutations. Future screening of large patient cohorts with pyrosequencing may contribute to the detection of more mutations in lung cancer because of the low limit of detections of this method and may contribute to a better understanding of the interaction of mutations and tumorigenesis.</p>","PeriodicalId":11235,"journal":{"name":"Diagnostic Molecular Pathology","volume":"22 1","pages":"22-7"},"PeriodicalIF":0.0000,"publicationDate":"2013-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/PDM.0b013e31825f5f93","citationCount":"9","resultStr":"{\"title\":\"Identification of uncommon PIK3CA mutations in lung cancer by using pyrosequencing.\",\"authors\":\"Verena Schildgen,&nbsp;Jessica Lüsebrink,&nbsp;Jan D Appel,&nbsp;Christine Wübben,&nbsp;Walburga Engel-Riedel,&nbsp;Corinna Ludwig,&nbsp;Erich Stoelben,&nbsp;Oliver Schildgen,&nbsp;Michael Brockmann\",\"doi\":\"10.1097/PDM.0b013e31825f5f93\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Phospatidylinositol-3-kinases (PI3K) play an important role in various cell processes. Oncogenic mutations in the PIK3CA gene, which codes for the catalytic subunit, have been identified in various malignancies and activate the PI3K/AKT/mTOR pathway, which is a critical driver of tumorigenesis.</p><p><strong>Methods: </strong>We tested 41 tumor samples with known KRAS, BRAF, and EGFR mutation status for the occurrence of mutations in the PIK3CA gene, using a pyrosequencing assay.</p><p><strong>Results: </strong>Pyrosequencing revealed 2 mutations (4.9%) in the PIK3CA gene, one in exon 9 and the other in exon 20. Both mutations have not been identified yet in lung tumor tissue.</p><p><strong>Discussion: </strong>The screening of our small patient cohort by pyrosequencing identified 2 mutations (4.9%) in PIK3CA, one in exon 9 (Q546H) and the other in exon 20 (M1043T). Both mutations have not been described in lung tumors yet and seem to be rather uncommon mutations. Future screening of large patient cohorts with pyrosequencing may contribute to the detection of more mutations in lung cancer because of the low limit of detections of this method and may contribute to a better understanding of the interaction of mutations and tumorigenesis.</p>\",\"PeriodicalId\":11235,\"journal\":{\"name\":\"Diagnostic Molecular Pathology\",\"volume\":\"22 1\",\"pages\":\"22-7\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1097/PDM.0b013e31825f5f93\",\"citationCount\":\"9\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diagnostic Molecular Pathology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/PDM.0b013e31825f5f93\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diagnostic Molecular Pathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/PDM.0b013e31825f5f93","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 9

摘要

磷酸肌醇-3激酶(phospatidylinositol -3 kinase, PI3K)在多种细胞过程中发挥重要作用。编码催化亚基的PIK3CA基因的致癌突变已在多种恶性肿瘤中被发现,并激活PI3K/AKT/mTOR通路,这是肿瘤发生的关键驱动因素。方法:我们使用焦磷酸测序法检测41例已知KRAS、BRAF和EGFR突变状态的肿瘤样本中PIK3CA基因突变的发生情况。结果:焦磷酸测序显示2个PIK3CA基因突变(4.9%),分别位于外显子9和外显子20。这两种突变尚未在肺肿瘤组织中发现。讨论:通过焦磷酸测序筛选我们的小患者队列,在PIK3CA中发现了2个突变(4.9%),一个在外显子9 (Q546H),另一个在外显子20 (M1043T)。这两种突变尚未在肺肿瘤中被描述,似乎是相当罕见的突变。由于这种方法的检测限较低,未来使用焦磷酸测序筛查大患者队列可能有助于检测更多的肺癌突变,并且可能有助于更好地了解突变和肿瘤发生的相互作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Identification of uncommon PIK3CA mutations in lung cancer by using pyrosequencing.

Introduction: Phospatidylinositol-3-kinases (PI3K) play an important role in various cell processes. Oncogenic mutations in the PIK3CA gene, which codes for the catalytic subunit, have been identified in various malignancies and activate the PI3K/AKT/mTOR pathway, which is a critical driver of tumorigenesis.

Methods: We tested 41 tumor samples with known KRAS, BRAF, and EGFR mutation status for the occurrence of mutations in the PIK3CA gene, using a pyrosequencing assay.

Results: Pyrosequencing revealed 2 mutations (4.9%) in the PIK3CA gene, one in exon 9 and the other in exon 20. Both mutations have not been identified yet in lung tumor tissue.

Discussion: The screening of our small patient cohort by pyrosequencing identified 2 mutations (4.9%) in PIK3CA, one in exon 9 (Q546H) and the other in exon 20 (M1043T). Both mutations have not been described in lung tumors yet and seem to be rather uncommon mutations. Future screening of large patient cohorts with pyrosequencing may contribute to the detection of more mutations in lung cancer because of the low limit of detections of this method and may contribute to a better understanding of the interaction of mutations and tumorigenesis.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
审稿时长
>12 weeks
期刊介绍: Diagnostic Molecular Pathology focuses on providing clinical and academic pathologists with coverage of the latest molecular technologies, timely reviews of established techniques, and papers on the applications of these methods to all aspects of surgical pathology and laboratory medicine. It publishes original, peer-reviewed contributions on molecular probes for diagnosis, such as tumor suppressor genes, oncogenes, the polymerase chain reaction (PCR), and in situ hybridization. Articles demonstrate how these highly sensitive techniques can be applied for more accurate diagnosis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信